Cohort study
Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease
- Prospective cohort study
- UK Biobank
- multivariable-adjusted Cox regression
Authors' conclusion
CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.
Study context
- Population
- Individuals aged 40 to 70 years with established atherosclerotic cardiovascular disease (ASCVD) and whole-exome sequences, UK Biobank
- Participants
- 13,129 individuals
- Exposure
- Clonal hematopoiesis of indeterminate potential (CHIP) vs no CHIP
- CHIPn = 665
- Outcome
- Composite of:
- ASCVD events
- All-cause mortality
- Follow-up
- Median 10.8 years
Main finding
As reported in the abstract
Each group vs no CHIPAdjusted hazard ratio (95% CI)P value
CHIPany CHIP
1.23(1.10–1.38)
P < 0.001Large CHIPlarge CHIP
1.34(1.17–1.53)
P < 0.001Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Primary outcome by driver gene (large clones) — Large TET2 CHIP vs No CHIP | 1.89 (1.40–2.55) | P < 0.001 | |
| Primary outcome by driver gene (large clones) — Large spliceosome CHIP vs No CHIP · SF3B1/SRSF2/U2AF1 | 3.02 (1.95–4.70) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. Published 23 May 2023. doi:10.1016/j.jacc.2023.03.401
Summarised from the published abstract; every number is checked against it